{
    "nctId": "NCT03964142",
    "briefTitle": "Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity",
    "officialTitle": "Randomized Controlled Trial on Comprehensive Exercise-based Cardiac Rehabilitation Programs for the Prevention of Anthracyclines and/or Anti-HER2 Antibodies-induced Cardiotoxicity in Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Cardiotoxicity, Cardiac Rehabilitation",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 122,
    "primaryOutcomeMeasure": "Change in left ventricular systolic function quantified by left ventricular ejection fraction and global longitudinal strain by transthoracic echocardiography",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* First diagnosis of breast cancer at early stages (I, II, III)\n* Treatment with anthracyclines and / or anti-HER-2 antibodies (trastuzumab and / or pertuzumab)\n* Possibility of completing a cardiac rehabilitation program (centre-based or telematic) and programmed visits.\n* Providing written informed consent.\n\nExclusion Criteria:\n\n* Patients with previous history of heart disease or heart failure.\n* Left ventricular dysfunction (left ventricular ejection fraction \\<53%) at baseline.\n* Metastatic disease.\n* Patients carrying an implantable cardioverter defibrillator.\n* Patients with physical or mental limitation to carry out an exercise program.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}